IFPMA Members involvement in countering the novel coronavirus (COVID-19)

The spread of the novel coronavirus epidemic is a major public health threat for all affected countries; and is of particular concern for those countries with weaker health systems who could be disproportionately impacted.

The R&D biopharmaceutical industry has welcomed the decision taken by the World Health Organization (WHO) on 30 January 2020 (IFPMA statement) to declare a public health emergency of international concern and reflects the serious nature of this public health threat. The industry is fully supportive of efforts that will ensure the scientific community can respond quickly to the challenges this epidemic faces. As a science-driven industry that aims to address some of the world’s biggest health care challenges, the research-based pharmaceutical industry clearly has a role to play in developing new and improved medicines and vaccines to help respond to this epidemic. R&D biopharmaceutical companies with potentially relevant knowhow have teams of scientists checking their libraries of potential assets that could fight coronaviruses.

The speedy sharing of the novel coronavirus pathogen sequence, followed by the declaration of an international emergency of public health concern, the convening of a global R&D Forum and the publication of a Global Research Roadmap, should further galvanise global collaboration with the private and public sectors as required for timely development of vaccines and treatments.

R&D biopharmaceutical companies are already engaging with existing networks such as CEPI (Coalition for Epidemic Preparedness Innovations) and Europe’s IMI (Innovative Medicines Initiative). In addition to R&D efforts, many R&D-based biopharmaceutical companies with a presence in China are donating funds, medicines, diagnostics and medical protective products.

Sharing the novel coronavirus (COVID-19) virus sequence

The rapid virus sequencing by the scientific community has allowed researchers to characterize and begin to understand the new threat posed by novel coronavirus (COVID-19). "Open Access" data sharing channels are the backbone to securing a response capacity, and have proven their worth with influenza networks.

The Global Initiative on Sharing All Influenza Data/GISAID Initiative, an open access platform partly funded by the private sector, has an important role to play in sharing of the first genome sequences of the novel coronavirus, and centralizing the collection of the novel coronavirus sequences, which is critical in speeding up the sharing of information among scientists as well as public health authorities.

Accelerating research and innovation for novel coronavirus (COVID-19)

The R&D biopharmaceutical industry (IFPMA and its members) is deeply concerned by the novel coronavirus (COVID-19) epidemic. Outbreaks of novel virus infections for which there is no known effective antiviral therapy present a serious threat to public health.

Currently, there is a focus on prevention and controlling the spread of this novel coronavirus, as there are no specific treatment options available for this particular strain of the virus. However, as of March 2020, there are a number of therapeutics currently in clinical trials in China and more than 20 vaccines in development for COVID-19.
As a science-driven industry that aims to address some of the world’s biggest health care challenges, the research-based pharmaceutical industry clearly has a role to play in developing new and improved medicines and vaccines to help respond to this epidemic.

Scientists checking libraries of assets - From the outset of the epidemic, member companies have reviewed their drug and vaccine portfolios to see if there is any research that could be of help. This analysis involved scientists assessing the companies’ libraries for potentially useful assets that could help with the development of new or repurposed treatments or vaccines to fight against the novel coronavirus.

Relevant assets include diagnostics and biomarkers, approved therapies or compounds in development which could be repurposed for use in treating patients with the coronavirus.

In addition, member companies are undertaking to identify any ACE inhibitors, protease inhibitors or immunotherapies that could be relevant in the context of novel coronavirus.

Companies & associations engaging in R&D collaboration – R&D biopharmaceutical companies are part of a wider research community which is collaborating to fast-track the development of therapeutics and diagnostics for the coronavirus to complement the ongoing global activities on novel coronavirus vaccines.

Collaborating in this way has the potential to accelerate development of resources to tackle this outbreak. It enables networks of centres of excellence that can deliver real impact and create a preparedness infrastructure which can be mobilized for future outbreaks.

**IFPMA member companies R&D efforts to contain the novel coronavirus**

**Treatment development**

- **AbbVie** announced it is partnering with global authorities to determine efficacy of HIV drug in treating COVID-19. AbbVie is supporting clinical studies and basic research with lopinavir/ritonavir, working closely with European health authorities and the U.S. Food and Drug Administration, Centers for Disease Control and Prevention, National Institutes of Health and Biomedical Advanced Research and Development Authority to coordinate on these efforts.

- **EFPIA is working with the Innovative Medicines Initiative (IMI)** on potential actions to support the collaborative research programs in order to fast-track the development of therapeutics.

- **Roche’s Actemra** has been approved by China on March 5 to treat Covid-19 patients with lung complications. Roche has donated nearly $2m-worth of Actemra to China to help the country manage the COVID-19 outbreak”. Actemra has been on the market since 2010 in Europe for treatment of several kinds of arthritis.

- **Gilead** is working with the Chinese health authorities to set up clinical trials to test the effectiveness of an experimental antiviral (remdesivir) aimed at treating Ebola and SARS.

- **Pfizer** announced that it completed a preliminary assessment of certain antiviral compounds that were previously in development and that inhibited the replication of coronaviruses similar to the one causing COVID-19 in cultured cells. Pfizer is engaging with a third party to screen these compounds under an accelerated timeline and currently expects to have the results back by the end of March.

- **Regeneron Pharmaceuticals**, announced an expanded agreement with the U.S. Department of Health and Human Services (HHS) to develop new treatments combating the novel coronavirus

- **Regeneron Pharmaceuticals and Sanofi SA** are racing to launch clinical trials exploring whether their arthritis drug could treat symptoms of the novel coronavirus infections.

- **Takeda** announced that it is initiating the development of a drug to treat people infected with the novel coronavirus. The experimental drug would be derived from the blood of coronavirus patients who have recovered from the respiratory disease.

**Vaccine development**
• CEPI and GSK will collaborate to help the global effort to develop a vaccine for the novel coronavirus. GSK is making its adjuvant technology available to support rapid development of candidate vaccines and is working with The University of Queensland, Australia.

• CSL Limited partnered with the University of Queensland’s COVID-19 vaccine development program. They will provide technical expertise as well as a donation of Seqirus’ proprietary adjuvant technology, MF59®, to their pre-clinical development program.

• GSK announced it would partner with the Chinese biotech company Clover Biopharmaceuticals. Under the partnership, GSK will provide Clover with its proprietary adjuvants – compounds that enhance the effectiveness of vaccines.

• Johnson & Johnson announces collaboration with U.S. Department of Health & Human Services (HHS) to accelerate development of a potential novel coronavirus vaccine.

• Sanofi announces it will work with the U.S. Department of Health & Human Services (HHS) HHS to develop a coronavirus vaccine.

Virus sequencing
• IFPMA is contributing funding to ensure the Global Initiative on Sharing All Influenza Data / GISAID Initiative has additional resources to support sharing the new coronavirus sequence.

Support for public health emergency in China

Across the R&D-based biopharmaceutical industry, the first concern is for those affected by the recent outbreak of the novel coronavirus.

In addition to monitoring the spread of the coronavirus in China, IFPMA and its member companies are working with their teams on the ground, and with the Chinese authorities to ensure people can get access to screening and healthcare. They are constantly reviewing how we can be most supportive during this outbreak; including ensuring that patients can continue to have access to the medicines they need.

IFPMA member companies with operations in China are responding to the Chinese government’s calls for drug makers to maintain or even increase their supplies to help the country throughout this public health crisis.

Member companies are consistently and diligently monitoring the supply chain for medicines both at their own sites and for their suppliers globally. This activity is an integral part of a company’s business continuity plan that is set up to deal with exactly these kinds of scenarios. These plans include critical inventory at distribution centers outside high-risk areas as well as working with external suppliers.

Providing support on the ground:
• Abbvie donated older antiviral drugs upon request from the Chinese government as an experimental option to support this growing public health crisis.

• Bayer has made substantial financial contributions as well as donations of several medicines to the Chinese Red Cross which is working together with the Chinese health authorities.

• Boehringer Ingelheim (BI) made financial donations to the Chinese Red Cross to purchase medical protective equipment as well as donations of medicines.

• CSL Limited donation of 1 million RMB to the China Red Cross in support of efforts to combat the epidemic.

• Johnson & Johnson has provided boxes containing laboratory-based investigations to the Chinese Centre for Disease and Prevention, which includes drug-screening for antiviral properties against the novel coronavirus, and donated 300 boxes of HIV medication to the Shanghai Public Health Clinical Center and Zhongnan Hospital of Wuhan University for use in research to support efforts in finding a solution against COVID-19.
• Lilly China made a cash donation of one million yuan (approximately $150,000) to the Red Cross, and the Lilly Foundation donated an additional $100,000 to Direct Relief, a U.S. non-profit organization. Direct Relief has made multiple airlift shipments of personal protective equipment and supplies into China. In addition, the Lilly Foundation made a $150,000 donation to Project HOPE to help with their efforts in response to the Coronavirus.
• Merck donated a total of $225,000 to Direct Relief, Project HOPE and Give2Asia, to support procurement and shipping of needed supplies to China, as well as aid for frontline health workers and hospitals. The company also donated ~$145,000 (one million RMB) to the Chinese Red Cross Foundation to support their ongoing response efforts.
• Pfizer has made cash contributions to its global NGO partners who have shipped supplies to hospitals in China.
• Pfizer Foundation has provided $500,000 in grants to support the provision of urgently needed aid and supplies to front-line healthcare workers. This grant funding supports urgent assistance by Direct Relief and Project HOPE, who are working with local partners on the ground to provide supplies and other support to healthcare workers and health systems in affected areas of China.
• Roche donated diagnostics tests, medical supplies and financial support. Genentech, a member of the Roche group, is working with Chinese health authorities and the government to help provide screening and health care, including supporting local health officials and hospitals in the Hubei Province.
• Roche donated nearly $2m-worth of Actemra to China to help the country manage the COVID-19 outbreak.
• Servier China has actively deployed its resources and purchased protective material to support healthcare professionals fighting the epidemic. As of the 3rd of February, Servier China provided several hospitals in Shaanxi and Beijing with disinfectant and other protective products. On February 10th, Servier China announced a donation of RMB 1 million (~140 000€) to the Chinese Red Cross to help prevent and control the coronavirus epidemic. This donation will be used to support first-line medical staff in 12 designated hospitals in Wuhan.

Pharmaceutical manufacturing supply chain

IFPMA and its member companies are monitoring the coronavirus situation in China and beyond closely. Currently, member companies are not aware of any near-term impacts on the availability of medicines and vaccines. The companies are continuously monitoring and proactively handling the situation as it’s developing and do not expect any long-term impact on the availability of medicines and vaccines, unless disruption due to the novel coronavirus outbreak is sustained over the next several months.

R&D biopharmaceutical companies are working proactively to prevent and mitigate potential shortages through close coordination with national regulatory authorities and other global stakeholders, including the World Health Organization.

IFPMA will continue to monitor the situation as it develops and will update this information accordingly. Last updated: 12 March 2020.

About IFPMA
IFPMA represents the research-based pharmaceutical companies and associations across the globe. The research-based pharmaceutical industry’s 2 million employees discover, develop, and deliver medicines and vaccines that improve the life of patients worldwide. Based in Geneva, IFPMA has official relations with the United Nations and contributes industry expertise to help the global health community find solutions that improve global health.
For further information, please contact:
Unjela Kaleem
Communications Director
u.kaleem@ifpma.org
+41 22 338 32 00

Abigail Jones
abigail@acumen-publicaffairs.com
+32 475 41 09 76